Evidence map›Paper›PMID 41909160›Full record

ArticleJCEM case reports2026

Unanticipated remission of primary hyperparathyroidism following cinacalcet.

Sara Ramadan, Shirin Haddady

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sara RamadanDepartment of Medicine, Boston Medical Center Brighton, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02135, USA.ORCID https://orcid.org/0000-0001-5608-0589
Shirin HaddadyDepartment of Medicine, Division of Endocrinology, Diabetes and Weight Management, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID https://orcid.org/0000-0002-1236-7980

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary hyperparathyroidism (PHPT) is the most common etiology of hypercalcemia in an ambulatory setting and often arises from adenomatous growth of one (occasionally more than one) parathyroid gland. Patients with severe and symptomatic hypercalcemia, renal insufficiency, nephrolithiasis, osteoporosis, and younger than 50 are candidates for surgical removal of parathyroid adenoma(s). Medical treatment with a calcimimetic agent is offered to improve severe hypercalcemia when surgery is refused or considered unsafe. Here, we report a 68-year-old man with severe hypercalcemia due to PHPT and coronary artery disease who had to undergo percutaneous coronary intervention and stent placement. Surgery for PHPT was delayed for 6 months, and he received cinacalcet to lower serum calcium. He developed hypocalcemia 6 months later. After discontinuation of cinacalcet, his serum calcium remained normal. Ultrasonography of the anterior neck showed again a hypoechoic lesion posterior to the right thyroid lobe (presumed to be a parathyroid adenoma) but with smaller dimensions. This case highlights a rare but clinically significant phenomenon: the possibility of durable remission and anatomical regression of parathyroid adenoma following cinacalcet administration.

Indexed as

calcium-sensing receptorcinacalcethypercalcemiamedical managementparathyroid adenomaprimary hyperparathyroidism

Identifiers

PMID41909160
PMCPMC13022825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.